Amphastar P (AMPH)

Currency in USD
19.00
-5.03(-20.93%)
Closed·
19.000.00(0.00%)
·
Unusual trading volume
AMPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
18.2819.52
52 wk Range
17.0331.26
Key Statistics
Prev. Close
24.03
Open
18.58
Day's Range
18.28-19.52
52 wk Range
17.03-31.26
Volume
1.98M
Average Volume (3m)
539.04K
1-Year Change
-21.1945%
Book Value / Share
17.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AMPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
26.43
Upside
+39.10%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Amphastar P News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

2 Buy
5 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 26.43
(+39.10% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Needham
Hold---DowngradeMay 08, 2026
Jefferies
Hold22.00+15.79%30.00DowngradeApr 20, 2026
Barclays
Hold23.00+21.05%30.00MaintainApr 08, 2026
Needham
Buy30.00+57.89%34.00MaintainFeb 27, 2026
Wells Fargo
Buy30.00+57.89%34.00MaintainFeb 27, 2026

Amphastar P Earnings Call Summary for Q1/2026

  • Q1 2026 EPS of $0.42 missed forecasts by 41.9%, down from $0.74 in Q1 2025; revenue rose marginally 0.4% to $171.2M year-over-year.
  • Gross margin improved significantly to 71% from 50% in Q1 2025; operating cash flow reached $47.8M despite earnings miss.
  • Pricing pressures on BAQSIMI and increased competition impacted performance; successful launch of AMP-007 with no immediate competition.
  • Company maintains guidance for mid-to-high single-digit unit growth in 2026; insulin aspart biosimilar expected to drive future growth.
  • Stock rose 0.54% to $23.9 despite earnings miss; 2 analysts revised earnings downward, signaling caution on near-term performance.
Last Updated: 2026-05-07, 11:48 p/m
Read Full Transcript

Earnings

Latest Release
May 07, 2026
EPS / Forecast
0.42 / 0.72
Revenue / Forecast
171.2M / 176.32M
EPS Revisions
Last 90 days

AMPH Income Statement

Compare AMPH to Peers and Sector

Metrics to compare
AMPH
Peers
Sector
Relationship
P/E Ratio
8.5x15.1x−0.5x
PEG Ratio
−0.320.090.00
Price/Book
1.1x3.9x2.6x
Price / LTM Sales
1.2x1.9x3.2x
Upside (Analyst Target)
16.6%1.5%47.8%
Fair Value Upside
Unlock25.9%5.9%Unlock

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Employees
1976

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
18.31M41.11%439.99M
Other Institutional Investors
22.24M49.93%534.38M
Public Companies & Retail Investors
3.99M8.95%95.80M
Total
44.54M100.00%1.07B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Applied Physics & Chemistry Laboratories, Inc.15.33%6,827,679129,726
BlackRock, Inc.12.26%5,461,969103,777

People Also Watch

30.99
HRMY
-1.37%
106.10
EHC
-0.98%
34.99
ALKS
-1.16%
81.86
ANIP
-2.44%

FAQ

What Is the Amphastar P (AMPH) Stock Price Today?

The Amphastar P stock price today is 19.00 USD.

What Stock Exchange Does Amphastar P Trade On?

Amphastar P is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Amphastar P?

The stock symbol for Amphastar P is "AMPH."

What Is the Amphastar P Market Cap?

As of today, Amphastar P market cap is 837.77M USD.

What Is Amphastar P's Earnings Per Share (TTM)?

The Amphastar P EPS (TTM) is 1.72.

When Is the Next Amphastar P Earnings Date?

Amphastar P will release its next earnings report on Aug 10, 2026.

From a Technical Analysis Perspective, Is AMPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Amphastar P Stock Split?

Amphastar P has split 0 times.

How Many Employees Does Amphastar P Have?

Amphastar P has 1976 employees.

What is the current trading status of Amphastar P (AMPH)?

As of May 09, 2026, Amphastar P (AMPH) is trading at a price of 19.00 USD, with a previous close of 24.03 USD. The stock has fluctuated within a day range of 18.28 USD to 19.52 USD, while its 52-week range spans from 17.03 USD to 31.26 USD.

What Is Amphastar P (AMPH) Price Target According to Analysts?

The average 12-month price target for Amphastar P is 26.43 USD, with a high estimate of 30 USD and a low estimate of 22 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +39.10% Upside potential.

What Is the AMPH Premarket Price?

AMPH's last pre-market stock price is 18.70 USD. The pre-market share volume is 56,270.00, and the stock has decreased by -5.33, or -22.18%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.